[Form 4] Nektar Therapeutics Insider Trading Activity
Robin W. Howard, President & CEO and director of Nektar Therapeutics (NKTR), sold a total of 11,832 shares of common stock under a Rule 10b5-1 trading plan on September 4-5, 2025. The sales were reported in several block transactions with weighted-average prices reported at $32.37, $33.54, $34.40, $35.80, $37.87, $38.82 and $39.89. Following these dispositions the reporting person beneficially owned 56,008 shares directly; an additional 28 shares are held indirectly by the reporting person’s spouse. The filer states the transactions were effected pursuant to a 10b5-1 plan and provides price ranges for each grouped trade.
Robin W. Howard, President e CEO nonché membro del consiglio di amministrazione di Nektar Therapeutics (NKTR), ha venduto complessivamente 11.832 azioni ordinarie nell'ambito di un piano di negoziazione Rule 10b5-1 nei giorni 4-5 settembre 2025. Le vendite sono state registrate in più blocchi, con prezzi medi ponderati pari a $32,37, $33,54, $34,40, $35,80, $37,87, $38,82 e $39,89. Dopo tali operazioni la persona che ha segnalato la vendita possedeva direttamente 56.008 azioni; ulteriori 28 azioni sono detenute indirettamente dal coniuge del dichiarante. Il depositante dichiara che le transazioni sono state eseguite in conformità a un piano 10b5-1 e fornisce gli intervalli di prezzo per ciascun gruppo di operazioni.
Robin W. Howard, presidente y director ejecutivo y miembro del consejo de Nektar Therapeutics (NKTR), vendió un total de 11.832 acciones ordinarias bajo un plan de negociación Rule 10b5-1 los días 4 y 5 de septiembre de 2025. Las ventas se informaron en varias transacciones por bloques, con precios promedio ponderados de $32.37, $33.54, $34.40, $35.80, $37.87, $38.82 y $39.89. Tras estas disposiciones, la persona que reporta poseía beneficiariamente 56.008 acciones de forma directa; otras 28 acciones están en manos de forma indirecta del cónyuge del declarante. El remitente indica que las operaciones se realizaron en virtud de un plan 10b5-1 y aporta los rangos de precio para cada grupo de operaciones.
로빈 W. 하워드(Robin W. Howard) Nektar Therapeutics(NKTR) 사장 겸 CEO, 이사직은 2025년 9월 4~5일 Rule 10b5-1 거래계획에 따라 보통주 총 11,832주를 매도했습니다. 해당 매도는 여러 블록 거래로 신고되었으며, 가중평균가격은 각각 $32.37, $33.54, $34.40, $35.80, $37.87, $38.82 및 $39.89로 보고되었습니다. 이들 처분 이후 신고인은 직접적으로 56,008주를 실질 보유하고 있으며, 추가로 28주는 신고인의 배우자가 간접 보유하고 있습니다. 신고자는 거래가 10b5-1 계획에 따라 이행되었음을 밝히고 각 그룹 거래별 가격 범위를 제공합니다.
Robin W. Howard, président-directeur général et administrateur de Nektar Therapeutics (NKTR), a vendu au total 11 832 actions ordinaires dans le cadre d'un plan de négociation Rule 10b5-1 les 4 et 5 septembre 2025. Les ventes ont été déclarées en plusieurs transactions par blocs, avec des prix moyens pondérés de 32,37 $, 33,54 $, 34,40 $, 35,80 $, 37,87 $, 38,82 $ et 39,89 $. À la suite de ces cessions, la personne déclarante détenait directement 56 008 actions ; 28 actions supplémentaires sont détenues indirectement par le conjoint de la personne déclarante. Le déposant indique que les transactions ont été effectuées conformément à un plan 10b5-1 et fournit les fourchettes de prix pour chaque groupe d'opérations.
Robin W. Howard, Präsident & CEO sowie Director von Nektar Therapeutics (NKTR), verkaufte insgesamt 11.832 Stammaktien im Rahmen eines Rule-10b5-1-Handelsplans am 4.–5. September 2025. Die Verkäufe wurden in mehreren Blocktransaktionen gemeldet, mit gewichteten Durchschnittspreisen von $32,37, $33,54, $34,40, $35,80, $37,87, $38,82 und $39,89. Nach diesen Veräußerungen besaß die meldende Person direkt 56.008 Aktien; weitere 28 Aktien werden indirekt von der Ehepartnerin/dem Ehepartner der meldenden Person gehalten. Der Einreicher gibt an, dass die Transaktionen gemäß einem 10b5-1-Plan ausgeführt wurden und nennt die Preisbereiche für jede gruppierte Transaktion.
- None.
- None.
Insights
TL;DR: Insider sales of 11,832 NKTR shares occurred under a 10b5-1 plan, reducing direct holdings to 56,008 shares; transactions span $32.01–$40.32.
The filing documents systematic disposals by the CEO and director executed under an established Rule 10b5-1 plan on September 4–5, 2025. The report aggregates multiple trades into seven grouped line items with weighted-average prices between $32.37 and $39.89 and disclosed underlying price ranges from $32.01 to $40.32. The filing is procedural and compliant: the 10b5-1 designation and price-range disclosures signal preplanned sales rather than ad-hoc disposals. No derivative transactions or other compensatory actions are reported.
TL;DR: Report shows prearranged insider selling via 10b5-1 plan; disclosure appears complete and signed by attorney-in-fact.
The Form 4 indicates the reporting person is both an officer (President & CEO) and a director, and that the trades were made pursuant to a 10b5-1 trading plan, which provides an affirmative defense under Rule 10b5-1. The form lists the aggregated share disposals, remaining direct beneficial ownership, and an indirect 28-share holding by spouse. The form is signed by Mark A. Wilson as attorney-in-fact and includes explanatory price ranges for each grouped sale, meeting standard disclosure expectations for such filings.
Robin W. Howard, President e CEO nonché membro del consiglio di amministrazione di Nektar Therapeutics (NKTR), ha venduto complessivamente 11.832 azioni ordinarie nell'ambito di un piano di negoziazione Rule 10b5-1 nei giorni 4-5 settembre 2025. Le vendite sono state registrate in più blocchi, con prezzi medi ponderati pari a $32,37, $33,54, $34,40, $35,80, $37,87, $38,82 e $39,89. Dopo tali operazioni la persona che ha segnalato la vendita possedeva direttamente 56.008 azioni; ulteriori 28 azioni sono detenute indirettamente dal coniuge del dichiarante. Il depositante dichiara che le transazioni sono state eseguite in conformità a un piano 10b5-1 e fornisce gli intervalli di prezzo per ciascun gruppo di operazioni.
Robin W. Howard, presidente y director ejecutivo y miembro del consejo de Nektar Therapeutics (NKTR), vendió un total de 11.832 acciones ordinarias bajo un plan de negociación Rule 10b5-1 los días 4 y 5 de septiembre de 2025. Las ventas se informaron en varias transacciones por bloques, con precios promedio ponderados de $32.37, $33.54, $34.40, $35.80, $37.87, $38.82 y $39.89. Tras estas disposiciones, la persona que reporta poseía beneficiariamente 56.008 acciones de forma directa; otras 28 acciones están en manos de forma indirecta del cónyuge del declarante. El remitente indica que las operaciones se realizaron en virtud de un plan 10b5-1 y aporta los rangos de precio para cada grupo de operaciones.
로빈 W. 하워드(Robin W. Howard) Nektar Therapeutics(NKTR) 사장 겸 CEO, 이사직은 2025년 9월 4~5일 Rule 10b5-1 거래계획에 따라 보통주 총 11,832주를 매도했습니다. 해당 매도는 여러 블록 거래로 신고되었으며, 가중평균가격은 각각 $32.37, $33.54, $34.40, $35.80, $37.87, $38.82 및 $39.89로 보고되었습니다. 이들 처분 이후 신고인은 직접적으로 56,008주를 실질 보유하고 있으며, 추가로 28주는 신고인의 배우자가 간접 보유하고 있습니다. 신고자는 거래가 10b5-1 계획에 따라 이행되었음을 밝히고 각 그룹 거래별 가격 범위를 제공합니다.
Robin W. Howard, président-directeur général et administrateur de Nektar Therapeutics (NKTR), a vendu au total 11 832 actions ordinaires dans le cadre d'un plan de négociation Rule 10b5-1 les 4 et 5 septembre 2025. Les ventes ont été déclarées en plusieurs transactions par blocs, avec des prix moyens pondérés de 32,37 $, 33,54 $, 34,40 $, 35,80 $, 37,87 $, 38,82 $ et 39,89 $. À la suite de ces cessions, la personne déclarante détenait directement 56 008 actions ; 28 actions supplémentaires sont détenues indirectement par le conjoint de la personne déclarante. Le déposant indique que les transactions ont été effectuées conformément à un plan 10b5-1 et fournit les fourchettes de prix pour chaque groupe d'opérations.
Robin W. Howard, Präsident & CEO sowie Director von Nektar Therapeutics (NKTR), verkaufte insgesamt 11.832 Stammaktien im Rahmen eines Rule-10b5-1-Handelsplans am 4.–5. September 2025. Die Verkäufe wurden in mehreren Blocktransaktionen gemeldet, mit gewichteten Durchschnittspreisen von $32,37, $33,54, $34,40, $35,80, $37,87, $38,82 und $39,89. Nach diesen Veräußerungen besaß die meldende Person direkt 56.008 Aktien; weitere 28 Aktien werden indirekt von der Ehepartnerin/dem Ehepartner der meldenden Person gehalten. Der Einreicher gibt an, dass die Transaktionen gemäß einem 10b5-1-Plan ausgeführt wurden und nennt die Preisbereiche für jede gruppierte Transaktion.
FAQ
What insider trades did NKTR report on this Form 4?
Were the sales executed under a Rule 10b5-1 plan for NKTR insider Robin Howard?
How many NKTR shares does Robin Howard beneficially own after the reported sales?
What price ranges were disclosed for the NKTR sales?
Who signed the Form 4 for these NKTR transactions?
